A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Seizures
- Focus Therapeutic Use
- 17 Mar 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 08 Jan 2019 Planned initiation date changed from 1 Jun 2018 to 1 Jan 2019.